Jazz Pharmaceuticals plc Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax
Jazz Pharmaceuticals plc (JAZZ) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax of -$100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax · last filed 2026-08-03
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2026-06-30 was -$100.00K, a 125.00% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2026-03-31 was -$200.00K, a 150.00% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2025-12-31 was $98.00K, a 86.99% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2025-09-30 was $411.00K, a 69.33% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2025 was $1.31M, a 72.65% decline from fiscal 2024.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2024 was $4.79M, a 40.02% increase from fiscal 2023.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2023 was $3.42M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2022 was $0.00.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 3 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 6 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$100.00K 10-Q · filed 2026-08-03 | -$300.00K 10-Q · filed 2026-08-03 | -$202.00K derived: sum of 3 quarters · filed 2026-08-03 | $209.00K derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | -$200.00K 10-Q · filed 2026-05-05 | -$102.00K derived: sum of 2 quarters · filed 2026-05-05 | $309.00K derived: sum of 3 quarters · filed 2026-05-05 | $709.00K derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $509.00K derived: sum of 2 quarters · filed 2026-02-24 | $909.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.31M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $411.00K 10-Q · filed 2025-11-05 | $811.00K derived: sum of 2 quarters · filed 2026-08-03 | $1.21M 10-Q · filed 2025-11-05 | $1.96M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-03 | $406.00K 10-Q · filed 2025-08-06 | $800.00K 10-Q · filed 2026-08-03 | $802.00K 10-Q · filed 2025-08-06 | $1.55M derived: sum of 3 quarters · filed 2026-08-03 | $2.89M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-05 | $396.00K 10-Q · filed 2025-05-07 | $1.15M derived: sum of 2 quarters · filed 2026-05-05 | $2.49M derived: sum of 3 quarters · filed 2026-05-05 | $3.84M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $753.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.09M derived: sum of 2 quarters · filed 2026-02-24 | $3.44M derived: sum of 3 quarters · filed 2026-02-24 | $4.79M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $1.34M 10-Q · filed 2025-11-05 | $2.68M derived: sum of 2 quarters · filed 2025-11-05 | $4.04M 10-Q · filed 2025-11-05 | $5.40M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $1.34M 10-Q · filed 2025-08-06 | $2.70M 10-Q · filed 2025-08-06 | $4.06M derived: sum of 3 quarters · filed 2026-02-24 | $5.35M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $1.36M 10-Q · filed 2025-05-07 | $2.72M derived: sum of 2 quarters · filed 2026-02-24 | $4.01M derived: sum of 3 quarters · filed 2026-02-24 | $4.78M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.65M derived: sum of 2 quarters · filed 2026-02-24 | $3.42M derived: sum of 3 quarters · filed 2026-02-24 | $3.42M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $1.29M 10-Q · filed 2024-11-07 | $2.06M derived: sum of 2 quarters · filed 2024-11-07 | $2.06M 10-Q · filed 2024-11-07 | $2.06M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $771.00K 10-Q · filed 2024-08-01 | $771.00K 10-Q · filed 2024-08-01 | $771.00K derived: sum of 3 quarters · filed 2025-02-26 | $771.00K derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$153.00K derived: sum of 2 quarters · filed 2024-02-28 | -$1.32M derived: sum of 3 quarters · filed 2024-02-28 | -$2.48M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | -$153.00K 10-Q · filed 2022-11-09 | -$1.32M derived: sum of 2 quarters · filed 2022-11-09 | -$2.48M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$1.17M 10-Q · filed 2022-08-03 | -$2.33M 10-Q · filed 2022-08-03 | ||||
| 2020-12-31 | -$3.40M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |